跳转至内容
Merck
CN

H146

4-羟基美芬妥英

≥98% (HPLC)

别名:

(±)-5-乙基-5-(4-羟苯基)-3-甲基海因, (±)-5-乙基-5-(4-羟苯基)-3-甲基羟基香豆素-2,4-二酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C12H14N2O3
化学文摘社编号:
分子量:
234.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
≥98% (HPLC)
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)

SMILES string

CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2

InChI key

OQPLORUDZLXXPD-UHFFFAOYSA-N

assay

≥98% (HPLC)

solubility

DMSO: >5 mg/mL

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

美芬妥英的 YP2C19 代谢物。

Application

药理活性研究:
  • 药物对代谢的影响
  • 体外微粒体细胞色素P450活性

用于电子捕获气相色谱法的分析物

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J Caslavska et al.
Journal of chromatography. B, Biomedical applications, 656(1), 219-231 (1994-06-03)
Phenotypes for hydroxylation can be predicted by using mephenytoin and dextromethorphan as substrates, whereas phenotypes for acetylation can be determined with caffeine as probe drug. After single-dose administration of one of these drugs, of two of them simultaneously, or of
Xunge Zhang et al.
Pharmaceutical biology, 58(1), 247-252 (2020-04-01)
Context: Cepharanthine (CEP) extracted from the roots of Stephania cepharantha Hayata (Menispermaceae), has a range of therapeutic potential in clinical conditions. Whether it affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.Materials and methods: The effects of
Xiao-Ping Chen et al.
Clinical pharmacology and therapeutics, 73(3), 264-271 (2003-03-07)
This study was designed to define the effect of low-dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects. Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持